Re-treatment of Prostate Cancer with Radiation Therapy

Main Article Content

Thomas Quinn, RT(T) CMD Harry Bushe, MS Shannon Higgins, CMD Joshua Taylor, CMD Yankhua Fan, PhD I-Lin Kuo, PhD Linda Ding, PhD Ronald Ebb, MD Jeffrey A Dann, MD, MBA William Walsh, MD Robert Babineau, MD Lacey McIntosh, DO Alan Goldstein, MD Zhong Jiang, MD Jesse Aronowitz, MD Maryann Bishop-Jodoin Thomas J. FitzGerald, MD

Abstract

As treatment for prostate cancer matures with many options for local, regional and systemic care, patients are living longer. Coupled with aggressive therapy for oligometastatic disease and improvements in multiple treatment pathways including radiopharmacy, both disease-free and overall survival are improving for many patients. Success can also bring new challenges that require new thought processes for care. In this paper we present two patients who had undergone previous radiation therapy for adenocarcinoma of the prostate with curative intent who required consideration for re-irradiation each more than 15 years away from primary management.

Keywords: Prostate cancer, intensity modulated radiation therapy, re-treatment management

Article Details

How to Cite
QUINN, Thomas et al. Re-treatment of Prostate Cancer with Radiation Therapy. Medical Research Archives, [S.l.], v. 9, n. 11, nov. 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2599>. Date accessed: 17 apr. 2024. doi: https://doi.org/10.18103/mra.v9i11.2599.
Section
Case Reports

References

1. Fuller D, Wurzer J, Shirazi R, et al. Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: Efficacy and toxicity of HDR-like SBRT. Int J Radiat Oncol Biol Phys. 2020;106:291-299.
2. Pasquier D, Martinage G, Janoray G, et al. Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: A retrospective multicenter study of the GETUG. Int J Radiat Oncol Biol Phy.s 2019;105:727-734.
3. Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiat Oncol. 2015;5:e615-e623.
4. Mbeutcha A, Chauveinc L, Bondiau PY, et al. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol. 2017;12:49.
5. Créhange G, Roach M III, Martin E, et al. Salvage reirradiation for local regional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother. 2014;18:524-534.
6. Baty M, Créhange G, Pasquier D, et al. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How? Cancer Radiother . 2019;23:541-558.
7. Taillez A, Bimbai AM, Lacornerie T, Le Deley MC, Lartigau EF, Pasquier D. Studies of intrafraction motion prostate motion during stereotactic irradiation in first irradiation and re-irradiation. Front Oncol. 2021;11:690422.
8. Lewin R, Amit U, Laufer M, et al. Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes. Radiat Oncol. 2021; 16: 114.
9. Cuccia F, Corradini S, Mazzola R, et al. MR-guided hypofractionated radiotherapy: Current emerging data and promising perspectives for localized prostate cancer. Cancers (Basel). 2021; 13: 1791.
10. Cuccia F, Nicosia L, Mazzola R, et al. Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer. Strahlenther Onkol. 2020;196:628-636.
11. Mohler JL, Halabi S, Ryan ST, et al. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer Prostatic Dis. 2019;22(2):309-316.